Stock Events

Stock Events

Hillevax

$2.09

8

-$0.01-0.48% Tuesday 19:58

Statistics

Day High

2.09

Day Low

2.09

52W High

2.17

52W Low

1.34

Volume

2,799,962

Avg. Volume

718,706

Mkt Cap

0

P/E Ratio

-

Dividend Yield

-

Dividend

-

Earnings

6NovExpected

Q4 2023

Q1 2024

Q2 2024

Q3 2024

Q1 2025

Q2 2025

Q3 2025

-0.97

-0.69

-0.4

-0.12

Expected EPS

-0.12

Actual EPS

N/A

Financials

-Profit Margin

Unprofitable

2021

2022

2023

2024

0Revenue

-147.27MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HLVX. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.

Takeda Pharmaceutical

Takeda Pharmaceutical Company works on vaccines, including those for gastroenterological diseases, directly competing with HilleVax's focus on norovirus vaccines.

GlaxoSmithKline plc has a broad portfolio in vaccines, including efforts in developing vaccines for viral gastroenteritis, making it a competitor.

Pfizer Inc. is involved in vaccine research and development, including efforts that could overlap with HilleVax's norovirus vaccine development.

Moderna, Inc. is known for its mRNA technology platform, which could be applied to develop vaccines against a wide range of diseases, including norovirus, competing with HilleVax.

BioNTech SE focuses on personalized immunotherapies and vaccines using mRNA technology, potentially including norovirus, making it a competitor.

Novavax, Inc. specializes in developing vaccines, including efforts that may target viruses similar to norovirus, positioning it as a competitor.

Sanofi operates in the vaccine sector, with a broad range of vaccine products and research that could encompass norovirus vaccine development.

Johnson & Johnson

Johnson & Johnson engages in the development of vaccines, including research into viral diseases that could compete with HilleVax's vaccine projects.

Arbutus Biopharma

Arbutus Biopharma Corporation works on antiviral therapies and vaccines, which could include efforts against norovirus or similar pathogens.

Vir Biotechnology

Vir Biotechnology, Inc. focuses on infectious diseases, including viral infections, potentially making it a competitor in the norovirus vaccine market.

About

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Show more...

CEO

Dr. Robert M. Hershberg M.D., Ph.D.

Employees

14

Country

United States

ISIN

US43157M1027

Listings

0 Comments

Share your thoughts

FAQ

What is Hillevax stock price today?▼

The current price of HLVX is $2.09 USD — it has decreased by -0.48% in the past 24 hours. Watch Hillevax stock price performance more closely on the chart.

What is Hillevax stock ticker?▼

Depending on the exchange, the stock ticker may vary. For instance, on exchange Hillevax stocks are traded under the ticker HLVX.

Is Hillevax stock price growing?▼

HLVX stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Hillevax has showed a +23.67% increase.

What is Hillevax revenue for the last year?▼

Hillevax revenue for the last year amounts to 0 USD.

What is Hillevax net income for the last year?▼

HLVX net income for the last year is -147.27M USD.

How many employees does Hillevax have?▼

As of April 18, 2026, the company has 14 employees.

In which sector is Hillevax located?▼

Hillevax operates in the Health & Wellness sector.

When did Hillevax complete a stock split?▼

Hillevax has not had any recent stock splits.

Where is Hillevax headquartered?▼

Hillevax is headquartered in Boston, United States.